ISSN:
1524-475X
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
Platelet-derived growth factor (PDGF-B) is a potent cell mitogen and chemotactic signal involved in normal wound healing. PDGF-B is present at decreased levels in diabetic wounds and has been shown to improve wound healing when applied in a topical form. However, clinical results with topical PDGF in the treatment of diabetic wounds have been equivocal. In this study, we investigated whether application of PDGF-B via gene therapy can effectively promote wound healing in the diabetic environment in an animal model. Retroviral vectors carrying the gene for human PDGF-B were constructed using the LNCX virus and the G418 resistance gene for selection (LN-PDGF-B), and transduced into mouse dermal fibroblasts. LN-PDGF-B transduced fibroblasts were seeded into alginate hydrogel scaffolds at a concentration of 25 × 106 cells/implant and implanted into 2 cm × 2 cm full thickness excisional dermal wounds created on the dorsae of genetically diabetic db/db mice. At 21 days, animals treated with LN-PDGF-B transduced cells suspended in alginate hydrogel demonstrated a significantly smaller epithelial gap (0.97 +/− 0.34 cm) than animals receiving untransduced mouse dermal fibroblasts alone (1.44 +/− 0.37 cm; P 〈 0.05) or animals receiving dermal fibroblasts transduced with LNCX viral vector alone (1.40 +/− 0.20 cm; P 〈 0.01). These results suggest tissue-engineered retroviral gene therapy with PDGF-B specifically promotes diabetic wound healing and may yield advances in the effective treatment of diabetic wounds.Supported by a grant from the American Diabetes Association
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1111/j.1067-1927.2005.130216bd.x
